By Colin Kellaher Shares of Akebia Therapeutics rose sharply in premarket trading Thursday after the biopharmaceutical company won U.S. Food and Drug Administration approval of its Vafseo drug.
The FDA-approved Vafseo tablets by Akebia Therapeutics for managing anemia in adult dialysis patients with chronic kidney disease. Learn about its once-daily oral HIF-PH inhibitor and global approval in 37 countries.
After a struggle, Akebia s oral CKD drug is approved by the FDA bioworld.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bioworld.com Daily Mail and Mail on Sunday newspapers.